Candida infective endocarditis
- 766 Downloads
Candida infective endocarditis (IE) is uncommon but often fatal. Most epidemiologic data are derived from small case series or case reports. This study was conducted to explore the epidemiology, treatment patterns, and outcomes of patients with Candida IE. We compared 33 Candida IE cases to 2,716 patients with non-fungal IE in the International Collaboration on Endocarditis—Prospective Cohort Study (ICE-PCS). Patients were enrolled and the data collected from June 2000 until August 2005. We noted that patients with Candida IE were more likely to have prosthetic valves (p < 0.001), short-term indwelling catheters (p < 0.0001), and have healthcare-associated infections (p < 0.001). The reasons for surgery differed between the two groups: myocardial abscess (46.7% vs. 22.2%, p = 0.026) and persistent positive blood cultures (33.3% vs. 9.9%, p = 0.003) were more common among those with Candida IE. Mortality at discharge was higher in patients with Candida IE (30.3%) when compared to non-fungal cases (17%, p = 0.046). Among Candida patients, mortality was similar in patients who received combination surgical and antifungal therapy versus antifungal therapy alone (33.3% vs. 27.8%, p = 0.26). New antifungal drugs, particularly echinocandins, were used frequently. These multi-center data suggest distinct epidemiologic features of Candida IE when compared to non-fungal cases. Indications for surgical intervention are different and mortality is increased. Newer antifungal treatment options are increasingly used. Large, multi-center studies are needed to help better define Candida IE.
KeywordsCoronary Artery Bypass Grafting Fluconazole Endocarditis Voriconazole Infective Endocarditis
This study was sponsored in part by a grant from Merck and Co., Inc. The sponsor had no role in the design and the conduct of the study, or in the collection, analysis, and interpretation of the data.
Research support from NICHD K23HD-0044799 (DKB).
Potential conflicts of interest
JWB: Research support from Astellas and Merck, Inc. Speaker’s bureau for Merck and Enzon. Consulting services for Pfizer and Enzon.
DKB: Research support from Astellas, Pfizer, Inc., Biosynexus, Cape Cod Associates, Inc., Johnson & Johnson, and Astra Zeneca. Fellowship support from Johnson & Johnson and MedImmune. All monies go to Duke University. Dr. Benjamin does not own any stock or hold financial interest in any organization listed above.
BB: Grant support from the Croatian Ministry of Science, no. 108-1080002-0102. Consulting services for Pliva Pharmaceuticals. Speaker’s bureau for Pliva Pharmaceuticals, Pharmasuiss Zagreb. Unrestricted research grant from Roche d.o.o. Zagreb.
ER: Research support from Theravance, Daiichi, Replidyne. Consulting services for Pfizer, Bayer, Wyeth, Teva, Replidyne, Schering Plough, Atox, and BiondVax.
VGF: Research funding from Theravance, Merck, Nabi, Inhibitex, Cubist, and the National Institutes of Health. Consulting for Astellas, Biosynexus, Cubist, Inhibitex, Merck, Johnson & Johnson, and is on the speakers’ bureaus for Cubist and Pfizer.
- 2.Benjamin DK Jr, Miró JM, Hoen B, Steinbach WJ, Fowler VG Jr, Olaison L, Habib G, Abrutyn E, Perfect J, Zass A, Corey GR, Eykyn S, Thuny F, Jiménez-Expósito MJ, Cabell CH; ICE-MD Study Group (2004) Candida endocarditis: contemporary cases from the International Collaboration of Infectious Endocarditis Merged Database (ICE-mD). Scand J Infect Dis 36(6-7):453–455PubMedCrossRefGoogle Scholar
- 9.del Castillo M, Wainsztein N, Klein F, Manganello S, Orellana N (2004) Treatment with caspofungin of Candida tropicalis endocarditis resistant to fluconazol. Medicina (B Aires) 64(2):152–154Google Scholar
- 11.Jiménez-Expósito MJ, Torres G, Baraldés A, Benito N, Marco F, Paré JC, Moreno A, Claramonte X, Mestres CA, Almela M, García de la María C, Pérez N, Schell WA, Corey GR, Perfect J, Jiménez de Anta MT, Gatell JM, Miró JM (2004) Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis 39(7):e70–73PubMedCrossRefGoogle Scholar
- 13.López-Ciudad V, Castro-Orjales MJ, León C, Sanz-Rodríguez C, de la Torre-Fernández MJ, Pérez de Juan-Romero MA, Collell-Llach MD, Díaz-López MD (2006) Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazole. BMC Infect Dis 6:73PubMedCrossRefGoogle Scholar
- 16.Fowler VG Jr, Miró JM, Hoen B, Cabell CH, Abrutyn E, Rubinstein E, Corey GR, Spelman D, Bradley SF, Barsic B, Pappas PA, Anstrom KJ, Wray D, Fortes CQ, Anguera I, Athan E, Jones P, van der Meer JT, Elliott TS, Levine DP, Bayer AS; ICE Investigators (2005) Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 293(24):3012–3021PubMedCrossRefGoogle Scholar
- 17.Wang A, Athan E, Pappas PA, Fowler VG Jr, Olaison L, Paré C, Almirante B, Muñoz P, Rizzi M, Naber C, Logar M, Tattevin P, Iarussi DL, Selton-Suty C, Jones SB, Casabé J, Morris A, Corey GR, Cabell CH; International Collaboration on Endocarditis—Prospective Cohort Study Investigators (2007) Contemporary clinical profile and outcome of prosthetic valve endocarditis. JAMA 297(12):1354–1361PubMedCrossRefGoogle Scholar
- 21.Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J; Caspofungin Invasive Candidiasis Study Group (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020–2029PubMedCrossRefGoogle Scholar
- 22.Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR (2005) Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 366(9495):1435–1442PubMedCrossRefGoogle Scholar